A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer.
10.3802/jgo.2013.24.2.154
- Author:
Seiji ISONISHI
1
;
Masaaki SUZUKI
;
Hiroaki NAGANO
;
Koichiro TAKAGI
;
Masahito SHIMAUCHI
;
Masakiyo KAWABATA
;
Kazuhiko OCHIAI
Author Information
1. Department of Obstetrics and Gynecology, Jikei Daisan Hospital, Tokyo, Japan. isonishi@jikei.ac.jp
- Publication Type:Original Article
- Keywords:
Chemotherapy;
Docetaxel;
Maintenance;
Ovarian cancer
- MeSH:
Bridged Compounds;
Carboplatin;
Disease Progression;
Drug Therapy, Combination;
Feasibility Studies;
Female;
Humans;
Maintenance Chemotherapy;
Neutropenia;
Ovarian Neoplasms;
Paclitaxel;
Peripheral Nervous System Diseases;
Recurrence;
Taxoids
- From:Journal of Gynecologic Oncology
2013;24(2):154-159
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To test the concept of taxane sequencing, this feasibility trial evaluated maintenance of docetaxel after paclitaxel and carboplatin combination chemotherapy in patients with stage IC-IV ovarian cancer. METHODS: All patients received debulking surgery followed by paclitaxel and carboplatin chemotherapy. Attainment of clinically defined complete or partial response was confirmed by image scanning. Maintenance of docetaxel started at an initial dose of 70 mg/m2 every 4 weeks for 6 cycles and was extended to 10 cycles unless disease progression and/or recurrence during the protocol therapy or unacceptable toxicities were seen. RESULTS: Stage subsets in 20 eligible patients were as follows: IIIB, 2 patients (10%); IIIC, 13 patients (65%); IV, 5 patients (25%). Neutropenia was common (40% with grade 3 or 4) and was most frequent during first or second cycle although the disabling peripheral neuropathy was not observed. Twelve patients completed protocol therapy (6< or =cycles), while 8 patients failed to complete 6-cycle chemotherapy, because of progressive disease (5 patients) or grade 4 toxicities (3 patients). Median PFS was 20 months and 3-year PFS rate was 12%. Median overall survival was 39 months and 3-year OS rate was 69%. CONCLUSION: Six cycles of single-agent docetaxel maintenance chemotherapy is feasible and generally tolerable to women with advanced ovarian cancer who attained a clinically defined response to initial paclitaxel and carboplatin based chemotherapy.
